Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UBX0101 single and repeat dose in knee osteoarthritis
NCT04229225Phase 1Completed
- Sponsor
- Unity Biotechnology
- Start
- Jan 2020
- Primary completion
- Sep 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of UBX0101 in knee osteoarthritis (OA) (4 arms), sponsored by Unity Biotechnology. Primary endpoint: Incidence of serious and non-serious adverse events at 24 weeks. Started Jan 2020; status: completed.
02
Drugs
UBX0101
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04229225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229225.